CN1172668C - 白屈菜红碱在制备药物中的应用 - Google Patents

白屈菜红碱在制备药物中的应用 Download PDF

Info

Publication number
CN1172668C
CN1172668C CNB988048248A CN98804824A CN1172668C CN 1172668 C CN1172668 C CN 1172668C CN B988048248 A CNB988048248 A CN B988048248A CN 98804824 A CN98804824 A CN 98804824A CN 1172668 C CN1172668 C CN 1172668C
Authority
CN
China
Prior art keywords
cells
chelerythrine
cell
radiation
apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988048248A
Other languages
English (en)
Chinese (zh)
Other versions
CN1255061A (zh
Inventor
R��R��κ��������ķ
R·R·魏克塞尔鲍姆
J·金塔尼斯
S·J·奇穆拉
D·W·库夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, Arch Development Corp filed Critical Dana Farber Cancer Institute Inc
Publication of CN1255061A publication Critical patent/CN1255061A/zh
Application granted granted Critical
Publication of CN1172668C publication Critical patent/CN1172668C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB988048248A 1997-03-25 1998-03-25 白屈菜红碱在制备药物中的应用 Expired - Fee Related CN1172668C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/826,814 US6025365A (en) 1997-03-25 1997-03-25 Chelerythrine and radiation combined tumor therapy
US08/826,814 1997-03-25

Publications (2)

Publication Number Publication Date
CN1255061A CN1255061A (zh) 2000-05-31
CN1172668C true CN1172668C (zh) 2004-10-27

Family

ID=25247609

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988048248A Expired - Fee Related CN1172668C (zh) 1997-03-25 1998-03-25 白屈菜红碱在制备药物中的应用

Country Status (12)

Country Link
US (1) US6025365A (enExample)
EP (1) EP0971710B1 (enExample)
JP (1) JP2001521552A (enExample)
CN (1) CN1172668C (enExample)
AT (1) ATE267599T1 (enExample)
AU (1) AU737613B2 (enExample)
CA (1) CA2284992A1 (enExample)
DE (1) DE69824165T2 (enExample)
DK (1) DK0971710T3 (enExample)
ES (1) ES2218814T3 (enExample)
PT (1) PT971710E (enExample)
WO (1) WO1998042339A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426351B1 (en) * 2000-08-11 2002-07-30 Dana-Farber Cancer, Inc. Chelerythrine-based therapies for cancer
WO2003005965A2 (en) * 2001-07-11 2003-01-23 Musc Foundation For Research Development Modulators of ceramidase and methods of use based thereon
US20030028097A1 (en) * 2001-08-03 2003-02-06 D'amico Anthony V. Immobilizer probe system and method
WO2004016211A2 (en) * 2002-08-08 2004-02-26 Vanderbilt University Pi3k antagonists as radiosensitizers
JP2004284961A (ja) * 2003-03-19 2004-10-14 Okinawa Pref Gov 抗腫瘍成分をサルカケミカンから抽出した製剤、食品または食品添加物
CN1292750C (zh) * 2003-06-02 2007-01-03 张平 植物来源总生物碱组合物及其药物制剂
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
KR100822887B1 (ko) 2006-10-12 2008-04-17 한국생명공학연구원 치매의 치료 또는 예방을 위한 조성물
ITMI20080284A1 (it) * 2008-02-22 2009-08-23 Indena Spa Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono
CN101904849A (zh) * 2010-08-19 2010-12-08 苏州大学 血根碱制备肿瘤放射治疗增敏药物的应用
CN102552264A (zh) * 2012-02-28 2012-07-11 苏州大学 血根碱在制备电离辐射防护剂中的应用
CN116407537A (zh) * 2023-03-03 2023-07-11 长春中医药大学 一种白屈菜红碱在制备用于治疗卵巢癌的药物中的用途
CN118304300B (zh) * 2024-04-12 2025-03-14 儋州市人民医院 一种具有麻醉作用的组合物及其在制备麻醉药物中的应用
CN119548502A (zh) * 2024-11-19 2025-03-04 中国药科大学 白屈菜红碱在制备黑色素瘤治疗药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US209331A (en) * 1878-10-29 Improvement in medical compounds
US433257A (en) * 1890-07-29 Salve
US2344830A (en) * 1940-08-15 1944-03-21 Wisconsin Alumni Res Found Composition of matter for the chemical fixation of diseased tissue preparatory for surgical removal
US4145412A (en) * 1977-02-14 1979-03-20 Vipont Chemical Company Composition for application to oral cavity and method for preparation thereof
US4406881A (en) * 1980-05-20 1983-09-27 Vipont Laboratories Antimicrobial agent
US4376115A (en) * 1980-08-05 1983-03-08 Mccrorey Howard S Method and composition for treating teeth and method for preparing same
US4599228A (en) * 1981-01-19 1986-07-08 Vipont Laboratories, Inc. Antimicrobial agent
US5324520A (en) * 1988-12-19 1994-06-28 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
US5137912A (en) * 1991-01-28 1992-08-11 National Science Council Of Republic Of China Chelerythrine inhibits platelet aggregation--a potential anti-aggregation drug
US5571797A (en) * 1994-05-11 1996-11-05 Arch Development Corporation Method of inducing gene expression by ionizing radiation
AU6714396A (en) * 1995-07-28 1997-02-26 Trustees Of Boston University Methods and compositions for treating cell proliferative disorders
HUP9601096A2 (hu) * 1996-04-26 1998-01-28 János Aradi Anti-HIV-aktivitással rendelkező gyógynövényalapú gyógyászati és gyógyhatású készítmény,és vegyületek

Also Published As

Publication number Publication date
CA2284992A1 (en) 1998-10-01
PT971710E (pt) 2004-09-30
CN1255061A (zh) 2000-05-31
ES2218814T3 (es) 2004-11-16
AU737613B2 (en) 2001-08-23
DK0971710T3 (da) 2004-09-27
ATE267599T1 (de) 2004-06-15
US6025365A (en) 2000-02-15
JP2001521552A (ja) 2001-11-06
WO1998042339A1 (en) 1998-10-01
DE69824165T2 (de) 2005-06-09
EP0971710A1 (en) 2000-01-19
DE69824165D1 (de) 2004-07-01
AU6869398A (en) 1998-10-20
EP0971710B1 (en) 2004-05-26

Similar Documents

Publication Publication Date Title
CN1172668C (zh) 白屈菜红碱在制备药物中的应用
CN1200714C (zh) 抗增生药与双萜三环氧化物制备治疗实体瘤药剂的用途
AU2006318212B2 (en) Oncogenic ras-specific cytotoxic compound and methods of use thereof
JP2023514568A (ja) ユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤を含む治療効果のある組み合わせ
CN1921846A (zh) 采用乙酰胆碱酯酶抑制剂和( 3ar)－1,3a,8－三甲基－1, 2, 3, 3a, 8,8a－六氢吡咯[2,3－b]吲哚－5－yl－苯基氨基甲酸酯的组合治疗
KR20180033194A (ko) 키랄 디아릴 매크로사이클 및 이것의 용도
CN1231694A (zh) 针对核糖核苷酸还原酶r1和r2组分的抗肿瘤反义序列
US8841319B2 (en) Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management
US7199122B2 (en) Methods for inhibiting angiogenesis
JP2002519311A (ja) 細胞死を誘発するための組成物と方法
EP1638574B1 (en) New pharmaceutical uses of staurosporine derivatives
CN1447686A (zh) Dfmo的d－对映体及其使用方法
CN1731998A (zh) 用于治疗、缓解和控制疼痛的包含选择性细胞因子抑制药物的组合物及使用方法
CN1649612A (zh) 细胞分化的诱导方法
US6426351B1 (en) Chelerythrine-based therapies for cancer
CN101068570A (zh) 双嘧达莫治疗血小板抑制剂的抗药性的用途
US20060160837A1 (en) Rapamycin compounds in the treatment of neurofibromatosis type 1
US20070275099A1 (en) MST1 modulation of apoptosis in cardiac tissue and modulators of MST1 for treatment and prevention of cardiac disease
US20040191168A1 (en) Tumor cell killing by cell cycle checkpoint abrogation combined with Inhibition of the classical mitogen activated protein (map) kinase pathway
CN1956710A (zh) 缓解疼痛的方法
CN1909896A (zh) 调节血管生成和癌细胞增殖的方法
Amino et al. YM-231146, a novel orally bioavailable inhibitor of vascular endothelial growth factor receptor-2, is effective against paclitaxel resistant tumors
US7468379B2 (en) Inhibition of osteolytic lesions by SRC kinase inhibitors
KR20060021865A (ko) 당뇨병을 치료하기 위한 티로신 키나제 억제제의 용도
Scuderi Involvement of TBK1 and PREP signalling pathways in Glioblastoma Multiforme progression: novel therapeutic perspectives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: CHICAGO UNIVERSITY

Free format text: FORMER OWNER: AZITHROMYCIN DEVELOPMENT CO., LTD.

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20050701

Address after: Illinois State

Co-patentee after: The Dana Farber Cancer Institute

Patentee after: Univ. of Chicago

Address before: Illinois State

Co-patentee before: The Dana Farber Cancer Institute

Patentee before: Arch Development Corp.

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1073049

Country of ref document: HK

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee